Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29209024 | 1.00 | LMNA (0.51) | LMNANOTUMTHRBMAPTDGAT1 | |
| SCHEMBL30336438 | 0.83 | LMNA (0.46) | LMNANOTUMTHRBMAPTDGAT1 | |
| SCHEMBL29209099 | 0.83 | LMNA (0.46) | LMNANOTUMTHRBMAPTDGAT1 | |
| SCHEMBL5270784 | 0.81 | NOTUM (0.63) | LMNANOTUMTHRBMAPTTP53 | |
| SCHEMBL5276056 | 0.80 | USP30 (0.50) | LMNANOTUMDGAT1PIK3CDPIK3CA | |
| SCHEMBL13190157 | 0.76 | DGAT1 (0.61) | DGAT1USP30 | |
| SCHEMBL4824285 | 0.73 | NAAA (0.49) | LMNANOTUMMAPTTP53 | |
| SCHEMBL31472162 | 0.73 | TP53 (0.44) | LMNANOTUMMAPTRXFP1TP53 | |
| SCHEMBL13190472 | 0.73 | DGAT1 (0.61) | DGAT1 | |
| SCHEMBL304544 | 0.72 | PDK1 (0.43) | LMNANOTUMMAPTKDRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-03 | — | — | US | disclosed |
| CN-117999259-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | LMNA 1562/4885NOTUM 4702/4885THRB 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.